Targeted Genetics officials anticipate that the cause of death of a subject in their gene therapy clinical trial in July will be disseminated histoplasmosis -- a fungal infection -- and not connected to the trial drug, H. Stewart Parker, CEO of Targeted Genetics, told The Scientist. The finding will be announced at the Monday (September 17) National Institutes of Health Recombinant DNA Advisory Committee meeting. "We believe strongly that it's very unlikely that this drug had anything to do with the death," said Parker. "We have to show that as conclusively as we can" at the meeting. As we linkurl:reported; in July, one patient in a clinical trial of tgAAC94, an adeno-associated virus (AAV) vector to treat inflammatory arthritis, got sick on July 24 and died July 29. The FDA halted the trial once the adverse effect had been reported. The patient was treated at the University of Chicago Medical...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?